HFS
GALT icon

Hantz Financial Services’s Galectin Therapeutics GALT Stock Holding History

Hantz Financial Services’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,083
Closed -$9K – 2454
2025
Q3 		$9K Buy
+2,083
New +$7.84K ﹤0.01% 1860

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Hantz Financial Services's GALT Position: Q4 2025 in Review

Hantz Financial Services sold out of Galectin Therapeutics (GALT) in Q4 2025, closing a stake of 2,083 shares — an estimated $9K sold.

Hantz Financial Services first reported a position in GALT in Q3 2025 and held it in 1 quarter. The position peaked at $9K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

  • Hantz Financial Services reported no remaining Galectin Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Hantz Financial Services sold 2,083 Galectin Therapeutics shares in Q4 2025, an estimated $9K.
  • Hantz Financial Services first reported a position in Galectin Therapeutics in Q3 2025 and held it in 1 quarter.
  • Hantz Financial Services's Galectin Therapeutics position peaked at $9K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on Hantz Financial Services's 13F filing for Q4 2025, filed 9 Feb 2026.